MISSION VIEJO, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board:AOLS) reported that researchers from National Jewish Health and the University of Colorado Anschutz Medical Campus have completed studies demonstrating that AEOL 10150 provides statistically significant protection of the skin in the 2-chloroethyl-ethylsulfide (CEES; half mustard) model of mustard gas exposure in mice and in a human cell culture model. Data were presented at the 4th Annual CounterACT Countermeasures Against Chemical Threats Network Research Symposium in San Francisco. There are currently no effective treatments for mustard gas exposure and AEOL 10150 is a major focus of a sponsored research grant awarded by the NIH Counteract program to National Jewish Health to identify an effective treatment. Sulfur mustards have been used in warfare since WWI and still pose a significant threat to civilian and military personnel. Mustard gas exposure can cause significant blistering of the skin as well as respiratory injury and fibrosis.
